MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Company Profile (NASDAQ:JUNO)

Consensus Ratings for (NASDAQ:JUNO) (?)
Ratings Breakdown: 1 Hold Rating(s), 12 Buy Rating(s)
Consensus Rating:Buy (Score: 2.92)
Consensus Price Target: $57.75 (41.76% upside)

Analysts' Ratings History for (NASDAQ:JUNO)
Show:
DateFirmActionRatingPrice TargetActions
6/6/2016FBR & CoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Raymond James Financial Inc.Initiated CoverageOutperform$52.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Cowen and CompanyInitiated CoverageOutperform$55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2016SunTrust Banks Inc.Reiterated RatingBuy$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/11/2016Maxim GroupReiterated RatingBuy$78.00 -> $80.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/8/2016Morgan StanleyBoost Price Target$48.00 -> $50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2016Leerink SwannReiterated RatingOutperform$67.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2016Deutsche Bank AGInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Citigroup Inc.Initiated CoverageBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman Sachs Group Inc.Lower Price Target$50.00 -> $41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/17/2016GuggenheimUpgradeNeutral -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/13/2016JPMorgan Chase & Co.Reiterated RatingOverweight$69.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/15/2015Standpoint ResearchUpgradeHold -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/22/2015Northland SecuritiesInitiated CoverageOutperform$64.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/2/2014 forward)
Earnings History for (NASDAQ:JUNO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/9/2016Q116($0.52)($0.78)$4.83 million$9.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415($0.47)($0.53)$4.79 million$4.15 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.41)($0.53)$6.41 million$1.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.37)($0.35)$2.03 million$12.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.35)($0.30)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2015Q414($0.33)($1.61)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for (NASDAQ:JUNO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.67)($0.67)($0.67)
Q2 20161($0.47)($0.47)($0.47)
Q3 20161($0.52)($0.52)($0.52)
Q4 20161($0.58)($0.58)($0.58)
(Data provided by Zacks Investment Research)
Dividend History for (NASDAQ:JUNO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for (NASDAQ:JUNO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/24/2016Richard KlausnerDirectorSell12,000$40.71$488,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2016Hyam LevitskyEVPSell12,418$42.77$531,117.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2016Steve HarrCFOSell30,000$43.32$1,299,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2016Hans Edgar BishopCEOSell90,750$46.42$4,212,615.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2016Bernard J CassidyGeneral CounselSell3,116$39.03$121,617.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2016Richard KlausnerDirectorSell12,000$40.00$480,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/19/2016Bernard J CassidyGeneral CounselSell3,200$43.12$137,984.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2016Richard KlausnerDirectorSell12,000$42.90$514,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/28/2016Anthony B EvninDirectorBuy8,000$36.58$292,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/22/2016Richard KlausnerDirectorSell12,000$40.00$480,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2016Bernard J CassidyGeneral CounselSell3,200$38.18$122,176.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2016Steve HarrInsiderSell5,000$45.00$225,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2016Richard KlausnerDirectorSell24,000$40.42$970,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Douglas K BrattonMajor ShareholderSell8,600,000$39.00$335,400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Steve HarrInsiderSell30,000$37.58$1,127,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2016Bernard J. CassidyGeneral CounselSell3,200$34.50$110,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Bernard J. CassidyGeneral CounselSell3,200$33.55$107,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2015Bernard J. CassidyGeneral CounselSell3,200$45.39$145,248.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2015Steve HarrinsiderSell35,000$46.43$1,625,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2015Bernard J. CassidyGeneral CounselSell3,200$52.97$169,504.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2015Richard KlausnerDirectorSell12,000$49.51$594,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/19/2015Bernard J. CassidyGeneral CounselSell3,200$49.85$159,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Richard KlausnerDirectorSell8,000$50.00$400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/12/2015Richard KlausnerDirectorSell16,000$50.00$800,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Bernard J. CassidyGeneral CounselSell11,850$42.50$503,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2015Bernard J. CassidyGeneral CounselSell11,850$40.15$475,777.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2015Bernard J CassidyGeneral CounselSell11,850$50.55$599,017.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Richard KlausnerDirectorSell8,000$53.34$426,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2015Douglas K BrattonMajor ShareholderSell40,000$54.75$2,190,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2015Anthony B EvninDirectorSell583,333$48.11$28,064,150.63View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2015Bernard J CassidyGeneral CounselSell11,850$51.34$608,379.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2015Douglas K BrattonMajor ShareholderSell270,000$51.13$13,805,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2015Richard KlausnerDirectorSell8,000$52.29$418,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Anthony B EvninDirectorSell583,333$52.88$30,846,649.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014Douglas K BrattonMajor ShareholderBuy625,000$24.00$15,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014Hal BarronDirectorBuy100,000$24.00$2,400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2014Douglas K BrattonMajor ShareholderBuy625,000$25.00$15,625,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for (NASDAQ:JUNO)
DateHeadline
07/01/16 04:49 PMNASA’s Juno Mission to Enter Jupiter’s Orbit on Fourth of July
07/01/16 04:49 PMJuno and the Deep Space Network: Bringing The Data Home
07/01/16 04:49 PMNASA's Juno closes in on Jupiter
07/01/16 04:49 PMNASA's Juno spacecraft enters Jupiter's magnetic field
07/01/16 04:49 PMWild Light Show, Strange Sounds Coming From Jupiter As Juno Spacecraft Approaches Orbit
07/01/16 04:49 PMJupiter Approach: What are NASA's hopes for Juno?
07/01/16 04:49 PMThe sounds of Juno approaching Jupiter are totally spooky
07/01/16 04:49 PMNASA’s Juno probe has entered Jupiter’s violent magnetosphere
07/01/16 04:49 PMNASA’s ‘armored tank’ Juno ventures into a fierce realm of radiation, hunting for Jupiter’s secrets
07/01/16 04:49 PMJuno set to arrive at Jupiter on July 4, a patriotic coincidence
07/01/16 07:37 AMSell-Side Recommendation & Price Target Projections on Juno Therapeutics, Inc. (NASDAQ:JUNO) - Telanagana Press
07/01/16 07:37 AMRecently Issued Stock Ratings For Juno Therapeutics, Inc. (NASDAQ:JUNO) - Fiscal Standard
06/30/16 07:40 AMAnalyst Rating Update on Juno Therapeutics (JUNO) - TheFounders Daily
06/30/16 07:40 AMJuno Therapeutics, Inc. (NASDAQ:JUNO) Company Rating and Target Watch - Telanagana Press
06/29/16 04:41 PMShare Update and Earnings Review for Juno Therapeutics, Inc. (NASDAQ:JUNO) - Press Telegraph
06/29/16 04:41 PMHC Stocks Broker Alerts: Edwards Lifesciences Corp (NYSE:EW), Juno Therapeutics Inc (NASDAQ:JUNO) - share market updates (press release)
06/29/16 07:37 AMTurn-Around Tuesday, Great Technicals, Closed at the Highs Going Away
06/28/16 04:43 PMTop Stock Pick for Quarter: Juno Therapeutics Inc. (NASDAQ:JUNO) - Engelwood Daily
06/27/16 04:46 PMJuno Therapeutics, Inc. (NASDAQ:JUNO) Earnings Glance and Target Price Review - Engelwood Daily
06/27/16 04:46 PMStrong Sell Calls Recommendations For Juno Therapeutics, Inc. (NASDAQ:JUNO) At 0 - Investor Newswire
06/27/16 09:08 AMJuno Therapeutics June 15th Short Interest Update - TheFounders Daily
06/27/16 09:08 AMJuno Therapeutics, Inc. (NASDAQ:JUNO) Broker Price Targets For The Coming Week - Fiscal Standard
06/27/16 09:08 AMBetter Buy: Bellicum Pharmaceuticals, Inc. vs. Juno Therapeutics, Inc. - Motley Fool
06/27/16 07:40 AMJuno Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JUNO-US : June 27, 2016 -
06/25/16 04:27 PMAre Analysts Bearish Juno Therapeutics Inc (NASDAQ:JUNO) After Last Week? - Press Telegraph
06/25/16 08:36 AMJuno Therapeutics, Inc. (NASDAQ:JUNO) Trading Down – Insiders Selling, Short Interest Growing
06/24/16 04:47 PMPrice Target Update on Juno Therapeutics (NASDAQ:JUNO) - Trade Calls
06/24/16 07:26 AMSpectacular Day for Wall Street
06/24/16 07:26 AMFollicular Lymphoma - Pipeline Review, H1 2016 - Research and Markets
06/23/16 05:11 PMStock on Trader's Radar: Juno Therapeutics Inc. (NASDAQ:JUNO) - iStreetWire
06/23/16 08:28 AMBlame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack' -
06/21/16 04:29 PMJUNO Crosses Below Key Moving Average Level
06/18/16 09:40 AMCould This Breakthrough Change Everything We Know About Treating Cancer? -
06/17/16 04:41 PMJUNO THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
06/17/16 03:07 PMJUNO THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/17/16 11:06 AMJuno Therapeutics, Inc. – Value Analysis (NASDAQ:JUNO) : June 17, 2016 -
06/17/16 07:34 AMAnalyst Opinions on: Juno Therapeutics Inc. (NASDAQ:JUNO), Primero Mining Corp. (NYSE:PPP) - Beacon Chronicle
06/17/16 07:34 AMTrading updates about two Stocks: Juno Therapeutics, Inc. (NASDAQ:JUNO) , Eleven Biotherapeutics, Inc. (NASDAQ ... - Street Updates
06/17/16 07:34 AMReview of Price Trends: STERIS Corporation (NYSE:STE) , Juno Therapeutics, Inc. (NASDAQ:JUNO) - Street Updates
06/16/16 04:56 PMGlobal Refractory Chronic Lymphocytic Leukemia (CLL) Pipeline Review 2016 - Research and Markets
06/16/16 04:56 PMGlobal Malignant Pleural Mesothelioma Pipeline Review 2016 - Research and Markets
06/16/16 04:30 PMSeattle's Juno praises partnership with Celgene at shareholder's meeting -
06/15/16 02:40 PMThree biotech funding trends to watch in Washington state -
06/15/16 09:27 AMStocks within investor Spotlight: ProNAi Therapeutics, Inc. (NASDAQ:DNAI) , Juno Therapeutics, Inc. (NASDAQ:JUNO) - Street Updates
06/14/16 09:36 AMSum Up The Parts: PXMG Could Be Worth $34
06/14/16 07:35 AMJuno Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JUNO-US : June 14, 2016 -
06/13/16 04:29 PMComplete Analysis of: Juno Therapeutics Inc. (NASDAQ:JUNO), Terex Corporation (NYSE:TEX) - Beacon Chronicle
06/13/16 09:03 AMCAR-T Drugmakers: The Big Winners at ASCO This Year? -
06/13/16 07:38 AMForm 4 Juno Therapeutics, Inc. For: Jun 09 Filed by: Bishop Hans Edgar - StreetInsider.com
06/13/16 07:38 AMHC Stocks in the Rumor: Juno Therapeutics Inc (NASDAQ:JUNO), Geron Corporation (NASDAQ:GERN) - share market updates (press release)
About

 logoJuno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno's product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Juno's other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: JUNO
  • CUSIP:
Key Metrics:
  • Previous Close: $40.69
  • 50 Day Moving Average: $41.70
  • 200 Day Moving Average: $38.89
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $4.12B
  • Current Quarter EPS Consensus Estimate: $-1.93 EPS
Additional Links:
(NASDAQ:JUNO) Chart for Saturday, July, 2, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha